Analysts upgrade Elevance, Centene shares as Medicaid margins expected to recover

Bank of America upgraded Elevance Health to Buy with a $435 target and doubled up on Centene to Buy with a $60 target from $34, citing Medicaid margins that appear near a trough and poised for a multi-year recovery. BofA estimates Centene’s Medicaid business is running near breakeven, creating a roughly $4 drag to 2026 EPS versus normalized earnings power of about $12 per share; Elevance has a larger ~$10 EPS headwind but benefits from a more diversified mix. Cantor Fitzgerald also upgraded Centene to Overweight and raised its target to $60, saying margin recovery in Medicaid, exchanges, and Medicare now looks increasingly likely.

Analysis

The main implication is not that managed care is suddenly cheap, but that the market is re-rating the duration of a margin trough. If Medicaid rates are already set behind cost inflation, then the earnings leverage in 2026-2028 is a function of utilization normalizing and state budgets eventually catching up; that creates a delayed but potentially steep operating inflection. The higher-quality expression is the diversified platform, since non-Medicaid earnings can absorb another year of noisy acuity and exchange risk without forcing a thesis break.

Second-order winners are the ancillary service and admin-heavy names that benefit when payers prioritize network management, claims discipline, and care coordination over pure enrollment growth. If the pricing cycle turns, the first beneficiaries are usually the firms with the cleanest medical loss ratio visibility and the most flexible capital deployment, while the laggards are those with concentrated state exposure and less ability to offset one bad Medicaid book with other fee-based businesses. The key nuance is that the market may be underestimating how much earnings power is being deferred rather than destroyed.

The main contrarian risk is timing: the stocks can rerate before fundamentals actually inflect, but they can also de-rate sharply if Q2 utilization and exchange mix come in worse than expected. A second, longer-dated risk is political: if membership rolls shrink later in the cycle, the recovered margins could be followed by a revenue air pocket in 2027-2028. That means the trade is better expressed as a 6-18 month valuation recovery than a blind long-term compounder bet.

Key Decisions for Investors

• Long ELV vs. CNC on a 6-12 month horizon: ELV offers the cleaner risk-adjusted way to play Medicaid margin normalization because diversification should mute downside if Q2 trend data disappoints; target a relative-value spread rather than outright beta.
• Buy CNC on pullbacks for a 12-24 month re-rating trade, but size it smaller than ELV; the upside is larger if margins normalize, yet the path is more volatile and dependent on evidence that Medicaid breakeven is truly the trough.
• Sell downside protection in ELV into strength: consider a 3-6 month put spread overwrite only if shares rally on confirmation of trend stabilization, because implied volatility likely overstates near-term fundamental risk.
• Pair long managed care quality names against short state-exposed, lower-diversification peers in the basket: the market should pay a premium for EPS visibility as the cycle turns, and that spread should widen if 2Q numbers validate the trough view.
• Use event-driven discipline around the next quarterly prints: if utilization or exchange acuity surprises negatively, reduce CNC first and keep ELV as the core exposure; the asymmetry favors waiting for confirmation rather than pre-emptively chasing the move.